
    
      Subjects who complete Part 1 of the study will be provided an opportunity to receive
      Formulation A under a continuous once daily dosing schedule during Part 2 of the study.
      Subjects enrolled in the second part of the study may continue to receive Formulation A under
      the continuous once daily dosing schedule for up to one year following the date of the last
      subject enrolled on study provided they continue to tolerate the drug, have no evidence of
      disease progression, and do not meet any of the protocol specific criteria for subject
      discontinuation.
    
  